D. Gritz and I. Wong, Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis Study, Ophthalmology, vol.111, issue.3, pp.491-500, 2004.
DOI : 10.1016/j.ophtha.2003.06.014

D. Wakefield and J. Chang, Epidemiology of Uveitis, International Ophthalmology Clinics, vol.45, issue.2, pp.1-13, 2005.
DOI : 10.1097/01.iio.0000155938.83083.94

R. Caorsi, S. Federici, and M. Gattorno, Biologic drugs in autoinflammatory syndromes, Autoimmunity Reviews, vol.12, issue.1, pp.81-86, 2012.
DOI : 10.1016/j.autrev.2012.07.027

N. Derevjanik, S. Vinores, W. Xiao, K. Mori, T. Turon et al., Quantitative assessment of the integrity of the blood-retinal barrier in mice, Invest Ophthalmol Vis Sci, vol.43, pp.2462-2467, 2002.

E. Rodrigues, M. Farah, M. Maia, F. Penha, C. Regatieri et al., Therapeutic monoclonal antibodies in ophthalmology, Progress in Retinal and Eye Research, vol.28, issue.2, pp.117-144, 2009.
DOI : 10.1016/j.preteyeres.2008.11.005

S. Lacomba, M. , M. Martín, C. , G. Galera et al., Aqueous Humor and Serum Tumor Necrosis Factor-?? in Clinical Uveitis, Ophthalmic Research, vol.33, issue.5, pp.251-255, 2001.
DOI : 10.1159/000055677

D. Jabs, J. Rosenbaum, C. Foster, G. Holland, G. Jaffe et al., Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel, American Journal of Ophthalmology, vol.130, issue.4, pp.492-513, 2000.
DOI : 10.1016/S0002-9394(00)00659-0

D. Saadoun, B. Bodaghi, B. Bienvenu, B. Wechsler, D. Sene et al., Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies, Autoimmunity Reviews, vol.12, issue.7, pp.774-783, 2013.
DOI : 10.1016/j.autrev.2013.02.002

M. Cordero-coma, T. Yilmaz, and S. Onal, Systematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated Uveitis, Ocular Immunology and Inflammation, vol.47, issue.2, pp.19-27, 2013.
DOI : 10.1001/jama.295.19.2275

G. Levy-clarke, D. Jabs, R. Read, J. Rosenbaum, A. Vitale et al., Expert Panel Recommendations for the Use of Anti???Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders, Ophthalmology, vol.121, issue.3, pp.785-796, 2014.
DOI : 10.1016/j.ophtha.2013.09.048

D. Jabs, R. Nussenblatt, and J. Rosenbaum, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, vol.140, pp.509-516, 2005.

J. Fine and R. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk, Journal of the American Statistical Association, vol.69, issue.446, pp.496-509, 1999.
DOI : 10.2307/2530374

P. Rosenbaum and D. Rubin, The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, pp.41-55, 1983.
DOI : 10.1093/biomet/70.1.41

E. Suhler, J. Smith, M. Wertheim, A. Lauer, D. Kurz et al., A Prospective Trial of Infliximab Therapy for Refractory Uveitis, Archives of Ophthalmology, vol.123, issue.7, pp.903-912, 2005.
DOI : 10.1001/archopht.123.7.903

E. Suhler, C. Lowder, D. Goldstein, T. Giles, A. Lauer et al., Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial, British Journal of Ophthalmology, vol.97, issue.4, pp.481-486, 2013.
DOI : 10.1136/bjophthalmol-2012-302292

M. Díaz-llopis, D. Salom, C. Garcia-de-vicuña, M. Cordero-coma, G. Ortega et al., Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients, Ophthalmology, vol.119, issue.8, pp.1575-1581, 2012.
DOI : 10.1016/j.ophtha.2012.02.018

B. Dobner, R. Max, M. Becker, C. Heinz, I. Veltrup et al., A three-centre experience with adalimumab for the treatment of non-infectious uveitis, British Journal of Ophthalmology, vol.97, issue.2, pp.134-138, 2013.
DOI : 10.1136/bjophthalmol-2011-301401

J. Kruh, P. Yang, A. Suelves, and C. Foster, Infliximab for the Treatment of Refractory Noninfectious Uveitis, Ophthalmology, vol.121, issue.1, pp.358-364, 2014.
DOI : 10.1016/j.ophtha.2013.07.019

S. Sugita, Y. Kawazoe, A. Imai, Y. Yamada, S. Horie et al., Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh??et's disease, Arthritis Research & Therapy, vol.14, issue.3, p.99, 2012.
DOI : 10.1080/02713680902741696

A. Arida, K. Fragiadaki, E. Giavri, and P. Sfikakis, Anti-TNF Agents for Beh??et's Disease: Analysis of Published Data on 369 Patients, Seminars in Arthritis and Rheumatism, vol.41, issue.1, pp.61-70, 2011.
DOI : 10.1016/j.semarthrit.2010.09.002

V. Calvo-río, R. Blanco, E. Beltrán, J. Sánchez-bursón, M. Mesquida et al., Anti-TNF-?? therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients, Rheumatology, vol.53, issue.12, pp.2223-2254, 2014.
DOI : 10.1093/rheumatology/keu266

S. Sugita, H. Takase, C. Taguchi, and M. Mochizuki, The Role of Soluble TNF Receptors for TNF-?? in Uveitis, Investigative Opthalmology & Visual Science, vol.48, issue.7, pp.3246-3252, 2007.
DOI : 10.1167/iovs.06-1444

J. Sheppard, A. Joshi, M. Mittal, K. Betts, S. Tari et al., Effect of Adalimumab on Visual Functioning (VFQ-25) in Visual-1 Trial Patients with Non-Anterior Non-Infectious Uveitis [abstract], Arthritis Rheumatol, vol.67, 2015.

D. Mendes, C. Alves, and F. Batel-marques, Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events, Journal of Clinical Pharmacy and Therapeutics, vol.31, issue.Suppl 1, pp.307-313, 2014.
DOI : 10.1111/jcpt.12148

S. Ramiro, C. Gaujoux-viala, J. Nam, J. Smolen, M. Buch et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.30, issue.(2), pp.529-535, 2014.
DOI : 10.1136/annrheumdis-2013-204575

J. Singh, C. Cameron, S. Noorbaloochi, T. Cullis, M. Tucker et al., Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis, The Lancet, vol.386, issue.9990, pp.258-65, 2015.
DOI : 10.1016/S0140-6736(14)61704-9

R. Nanau and M. Neuman, Safety of Anti-Tumor Necrosis Factor Therapies in Arthritis Patients, Journal of Pharmacy & Pharmaceutical Sciences, vol.17, issue.3, pp.324-61, 2014.
DOI : 10.18433/J3WP4F

I. Westhovens, R. Lories, R. Westhovens, P. Verschueren, K. Vlam et al., Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR), Clin Exp Rheumatol, vol.32, pp.71-76, 2014.

G. Simonini, A. Taddio, M. Cattalini, R. Caputo, D. Libero et al., Prevention of flare recurrences in childhood-refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab, Arthritis Care & Research, vol.23, issue.Suppl, pp.612-618, 2011.
DOI : 10.1002/acr.20404

M. Zannin, C. Birolo, V. Gerloni, E. Miserocchi, I. Pontikaki et al., Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry, The Journal of Rheumatology, vol.40, issue.1, pp.74-79, 2013.
DOI : 10.3899/jrheum.120583

K. Thorlund, E. Druyts, E. Mills, R. Fedorak, and J. Marshall, Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients na??ve to anti-TNF therapy: An indirect treatment comparison meta-analysis, Journal of Crohn's and Colitis, vol.8, issue.7, pp.571-581, 2014.
DOI : 10.1016/j.crohns.2014.01.010

J. Liu, G. Sylwestrzak, A. Ruggieri, and A. Devries, Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn???s Disease: A Comparison of Effectiveness and Safety, Journal of Managed Care & Specialty Pharmacy, vol.21, issue.7, pp.559-566, 2015.
DOI : 10.18553/jmcp.2015.21.7.559

W. Mei, H. Hu, Y. Liu, Z. Li, and W. Wang, Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis, World J Gastroenterol, vol.21, pp.6044-6051, 2015.

J. Borrás-blasco, D. Casterá, X. Cortes, F. Abad, J. Rosique-robles et al., Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults, Int. Journal of Clinical Pharmacology and Therapeutics, vol.53, issue.05, pp.377-390, 2015.
DOI : 10.5414/CP202171